Summary of Recommendations and Suggestions
1. In adult patients with cough associated with lung cancer that persists despite cancer treatment, we suggest, as a first step, that a comprehensive assessment according to a published, evidence-based management guideline be undertaken to identify any co-existing causes linked with cough and initiate treatment accordingly (Ungraded, Consensus Based Statement).
2. In adult patients with lung cancer experiencing cough despite anticancer treatment, we suggest cough suppression exercises as alternative or additional to pharmacological therapy where such services are available (Grade 2C).
3. In adult patients with cough due to localized endobronchial disease for whom surgery, chemotherapy, or external beam radiation are not indicated, we suggest the use of endobronchial brachytherapy where such specialist facilities are available and in suitable patients (Grade 2C).
4. In adult patients with lung cancer who require a pharmacological approach for the treatment of cough, we suggest an initial trial with demulcents such as butamirate linctus (syrup) or simple linctus (syrup) or glycerin-based linctus (syrup) where available (Grade 2C).
5. In adult patients with lung cancer experiencing cough that does not respond to demulcents, we suggest pharmacological management using an opiate-derivative titrated to an acceptable side-effect profile (Grade 2C).
6. In adult patients with lung cancer experiencing opioid-resistant cough, we suggest a peripherallyacting antitussive (where available), such as levodropropizine, moguisteine, levocloperastine or sodium cromoglycate (Grade 2C).
7. In adult patients with lung cancer experiencing opioid-resistant cough that does not respond to peripheral antitussives, we suggest a trial with local anesthetics, including nebulized lidocaine/ bupivacaine or benzonatate (Ungraded, Consensus Based Statement).
8. In adult patients with intractable cough due to lung cancer in whom surgery, chemotherapy, external beam radiation, brachytherapy and the previously mentioned nonpharmacological and pharmacological approaches are ineffective or not indicated, we suggest that clinicians consider performing N-of-1 randomized controlled trials to determine if any of the following drugs might be of benefit in controlling cough because none have been definitively shown to be effective nor devoid of side effects: diazepam, gabapentin, carbamazepine, baclofen, amitriptyline, thalidomide (Ungraded, Consensus Based Statement).
Cough among patients with lung cancer is a common symptom affecting 57% of them as shown in a study of 223 consecutive outpatients with lung cancer. 1 In the same study, one-half of the patients felt their cough warranted treatment, and 23% reported their cough to be painful, reporting a median visual analog scale score of 32 mm (25th-75th interquartile range, 20-51; range, 0-100; high scores ¼ worse cough severity). Although many cancer symptoms are managed well in clinical practice, the management of cough is lagging behind, with health professionals often using inconsistent approaches to manage cough in a field with a minimal high-level evidence base. 2, 3 Treatment decisions by patients are also significantly influenced by the possibility of reduction of tumor-associated symptoms, including primarily the symptoms of cough, shortness of breath, and pain. 4 Nevertheless, symptom management research in lung cancer care is fairly unbalanced, with some symptoms, including cough, receiving minimal attention in the literature.
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Cough is also an important determinant of quality of life. In a lung cancer study in 450 patients in the United States, 6 with samples similar to those in France and Germany (n ¼ 613 and 600, respectively), 7 cough, alongside loss of appetite, pain, and shortness of breath, was a significant predictor of quality of life. The same set of four symptoms has been linked with significant decreases in quality of life in patients with lung cancer in another study. 8 A study about the experience of patients with lung cancer with cough clearly showed the impact from this symptom on socializing, the embarrassment from cough in public places, and the psychological effects experienced by patients. 9 It is now clear that cough has complex interrelationships with other symptoms, including breathlessness and fatigue, forming a symptom cluster, 10 suggesting the need for a more comprehensive management of this symptom.
Most physicians use approaches based on experience and trial and error rather than evidence, and much of the treatment of cancer-related cough is geared toward the use of opioids. The American College of Chest Physicians (CHEST), in the past, has made an attempt to develop recommendations for the management of cough as part of a set of guidelines for a number of symptoms affecting patients with lung cancer 11, 12 ; however, the three recommendations presented were broad, reflecting the difficulty in making more specific recommendations. Two more guidelines have been developed, one from a UK task force evaluating research in cough management in lung cancer 13 and another focusing on chronic cough in palliative care. 14 These two guidelines have focused only on the pharmacologic management of cough. Consequently, there is a need to update and consolidate these guidelines by using current evidence and a more stringent process of evaluation of the recommendations.
In this regard, CHEST assessed the existing guidelines and an updated Cochrane systematic review 15 alongside other systematic reviews to propose an evidence-based set of specific guidelines for the symptomatic management of cough among patients with lung cancer that persists and is bothersome despite lung cancer treatment with surgery or systemic anticancer treatment such as chemotherapy or (external-beam) radiotherapy. Lung cancer treatments can also cause cough as a side effect, particularly in the context of radiation-induced fibrosis. Hence, the current guideline focuses on the management of cough beyond anticancer treatments. The specific aims of the current guidelines were to (1) evaluate the existing evidence in the management of cough related to lung cancer and (2) develop a set of recommendations and/or suggestions for the management of cough beyond initial lung cancer treatments.
Materials and Methods
The methodology of the CHEST Guideline Oversight Committee 16 was used to select the Expert Cough Panel Chair and the international panel of experts to synthesize the evidence and to develop the recommendations and suggestions that are contained within this article. In addition to the quality of the evidence, the recommendation and suggestion grading also includes a strength-ofrecommendation dimension, used for all CHEST Guidelines. 16 In the context of practice recommendations, a grade 1 recommendation is a strong recommendation and applies to almost all patients, whereas a grade 2 recommendation is weak and conditional and applies to only some patients. The strength of recommendation here is based on consideration of three factors: balance of benefits to harms, patient values and preferences, and resource considerations. Harms incorporate risks and burdens to the patients that can include convenience or lack of convenience, difficulty of administration, and invasiveness. These, in turn, impact patient preferences. The resource considerations go beyond economics and should also factor in time and other indirect costs. We have considered these parameters in determining the strength of the recommendations or suggestions and associated grades.
The findings of a Cochrane systematic review that was updated in 2015 15 were used to support the evidence-graded recommendations or suggestions. The initial Cochrane systematic review and the subsequent update were carried out by the first author (A. M.). The process of review of previous studies identified in the systematic review included assessment of the study quality or risk of bias by using the Cochrane quality assessment tool. This is a seven-item tool exploring selection-, performance-, detection-, attrition-, and reporting-related biases in a study. When the quality of studies included in the systematic review 15 were checked using the Documentation and Appraisal Review Tool tool, 17 similar results indicating poor quality of included studies were found. Because the search for articles for the Cochrane systematic review ended just before work on this guideline article began, no additional literature search took place for this article. A highly structured consensusbased Delphi approach was used to provide expert advice on all guidance statements. The total number of eligible voters for each guidance statement did not vary because none were recused from voting on any particular statements because of their potential conflicts of interest. Transparency of process was documented. Further details of the methods related to conflicts of interest and transparency have been published elsewhere. 16 On the basis of the systematic review 15 and the Delphi method described, the lung cancer cough panel writing group developed guideline recommendations or suggestions. These then underwent review and voting by the full cough panel. For a recommendation or suggestion to be accepted, it had to be voted on by 75% of the cough panelists and achieve ratings of strongly agree or agree by 80% of the voting panelists. Agreement was achieved by 81% to 96% of those voting in the current recommendations. No panelist was excluded from voting.
Results
The recommendations and suggestions that follow are largely based on the updated Cochrane systematic review 15 that included a comprehensive search of multiple databases without language restrictions. An overview of the studies available in cough related to lung cancer is shown in Table 1 , using the Grading of Recommendations, Assessment, Development, and Evaluation framework. 18 The review identified 17 studies, eight testing brachytherapy or laser or photodynamic therapy and nine testing a variety of drugs for the management of cough among patients with lung cancer. The total sample included 1,390 patients, among whom 1,231 had mostly lung cancer. If a mixed sample of patients was used, data were extracted for the cancer subsample when possible. Overall, there was absence of credible evidence, and the majority of studies were of low methodologic quality and at high risk of bias.
journal.publications.chestnet.org 1. In adult patients with cough associated with lung cancer that persists despite cancer treatment, we suggest, as a first step, that a comprehensive assessment according to a published, evidence-based management guideline be undertaken to identify any co-existing causes linked with cough and initiate treatment accordingly (Ungraded, Consensus Based Statement).
Summary of the Evidence and Interpretation
Vertigan and Gibson 22 reviewed the work done in chronic refractory cough and the role of speech pathology and cough suppression interventions that consist of education, strategies to control cough, vocal hygiene training, and psychoeducation. Results presented in a review of a single trial of patients with respiratory diseases 23 showed that 88% of patients improved their cough in the speech pathology group vs 14% in the control group. In a systematic review of cough management trials in respiratory diseases other than lung cancer, cough suppression interventions also showed promising results. 24 The same is further supported by another systematic review of five trials in refractory chronic cough 25 in which a package of cough suppression exercises given over three to four sessions was linked with significant improvements in cough frequency, cough severity, and cough-related quality of life. Cough suppression exercises refer to a number of approaches, including education, identifying cough triggers, cough suppression techniques (ie, pursed lip breathing, swallowing, sipping water), improvements in laryngeal and vocal hygiene and hydration, breathing exercises, and counseling. In a more recent feasibility trial in 101 patients with lung cancer experiencing a respiratory distress symptom cluster (breathlessness, cough, fatigue), participants found benefit from an intervention package educating them on how to manage this symptom cluster with specific nonpharmacologic approaches, including cough suppression techniques and diaphragmatic breathing. 27 A large trial to test this feasibility trial further is now ongoing in the United Kingdom. Speech pathology training is minimally used in current health care settings primarily because of limited availability of speech therapy services. However, the use of broader cough suppression exercises may be an area to enhance in future provision of care and identify further roles for speech therapists and respiratory physiotherapists in clinical practice, if results from future trials in lung cancer are consistently positive.
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Summary of Evidence and Interpretation
Endobronchial brachytherapy in a variety of doses seemed to improve cough in selected participants, suggesting that possibly the lowest effective dose should be used to minimize side effects. 15 The studies reviewed [28] [29] [30] [31] [32] [33] [34] were all uncontrolled comparative trials (mostly prospective ones), although it would have been unethical to carry out randomized trials with such a treatment approach. Photodynamic therapy was examined in one study, 35 and, although improvements in cough were observed, its role in relation to other therapies for cough was unclear. When brachytherapy is indicated but not locally available, patients should be transferred to a facility where it is available. Endobronchial brachytherapy should be considered particularly for patients with small or endobronchial tumors or limited disease or in whom the tumor has extended into the large airways; otherwise, external-beam radiotherapy (or a combination of the two) may be more effective.
In using endobronchial brachytherapy, we suggest the lowest dose and fractionated schedule (eg, a single fraction of 10 Gy, two fractions of 7-8 Gy, or three fractions of 5 Gy), as this approach is linked with a good response and a lower number of side effects. It is worth noting that external-beam radiation of one or two fractions can also improve thoracic symptoms, as shown in a systematic review, 36 and this approach should be considered if facilities for endobronchial brachytherapy are not available. Nevertheless, as endobronchial brachytherapy can also be associated with significant risk of hemoptysis and other complications, depending on the type of lesion and the area of application, a pharmacologic therapy trial may be more appropriate to start with.
It may be appropriate to start pharmacologic treatment at the same time with the previous two recommendations, especially if the cough is severe. This takes into consideration the fact that such specialist services may not be widely available, and, if they are, there are practical considerations in their delivery and their effect may not be immediate. quality, and they are perhaps not as effective as physicians would ideally like. In the Cochrane systematic review, 15 there was a double-blind randomized trial with positive results from using codeine 30 mg twice a day with phenyltoloxamine 10 mg 40 ; one with dihydrocodeine, 41 and one comparing morphine with codeine. 42 However, there have been a number of case reports providing some evidence of the beneficial effect of morphine, methadone, pholcodine, and hydromorphone, summarized in a scholarly review, 43 and a phase II trial using hydrocodone. 44, 45 For patients with lung cancer experiencing cough for whom treatment with an opioid derivative is indicated, we suggest pholcodine or hydrocodone (where available) or dihydrocodeine or morphine. Codeine is less preferred (despite being the most researched drug in this field) because of its greater side effect profile compared with those of other opioids, as commented on by many experts (personal communication with palliative medicine experts). Morphine should be used if the cough is not suppressed by other opioid derivatives or other means, including other centrally acting antitussives such as dextromethorphan. The patient's previous exposure to opioids will dictate the initial starting dose.
Many patients with advanced lung cancer may already be receiving opiates for other symptoms (eg, pain or breathlessness). If patients are already receiving morphine, sometimes increasing the dose by 20% may be helpful, although this is based on experience rather than any evidence. For patients with lung cancer who are experiencing nonspecific cough and who are in the palliative stage of their illness, we suggest a bedtime dose of codeine/pholcodine or morphine, as this approach may help suppress cough and induce an undisturbed sleep, although again there is no evidence for this (but physicians invariably use this approach).
Among peripherally acting antitussives, levodropropizine is probably equally effective to dihydrocodeine or moguisteine and with possible earlier cough reductions than with dextromethorphan. This was suggested by a systematic review of four trials (two randomized trials testing levodropropizine against dihydrocodeine and moguisteine and two nonrandomized placebo-controlled studies, all with important limitations and high risk of bias). 46 The major methodologic limitations of the studies reviewed make these results less convincing, and further research is necessary before any concrete conclusions are derived. Because some of these drugs are not available in many countries, the choice of treatment may be dictated primarily by availability rather than pharmacologic parameters.
Local anesthetics, such as nebulized lidocaine, have been suggested to be helpful in case studies 47, 48 and are commonly used in palliative care for intractable cough that has not responded to any other approaches. This is also supported by findings from a systematic review of cough management approaches. 24 Hence, we suggest that such local anesthetics be tried when other pharmacologic approaches have failed to manage cough among patients with lung cancer. As local anesthetics can increase the risk of aspiration, which can be prevalent in frail patients with cancer, aspiration risk should be assessed prior to the use of this type of treatment for cough.
Doses used in the medications mentioned earlier vary from country to country. Table 3 , shown originally in a previous cough guideline, 13 provides indicative doses. 4. In adult patients with lung cancer who require a pharmacological approach for the treatment of cough, we suggest an initial trial with demulcents such as butamirate linctus (syrup) or simple linctus (syrup) or glycerol-based linctus (syrup) where available (Grade 2C).
As the evidence described earlier is of generally low quality and the level of confidence is fairly low, it is likely that, despite best efforts as provided according to the previous recommendations, some patients will not respond to the suggested treatment. Physicians need to be aware that these cough management strategies, although based on the available evidence, are not necessarily optimal or effective enough, and discretion in their use should be exercised. The duration of treatment is an issue to consider, too: Although the evidence for this is minimal, if a short course of treatment does not lead to improvements, the treatment should be discontinued and another approach should be tried. Hence, ongoing research on the unmet need for better antitussive approaches in the lung cancer population is urgently needed. In managing cough among patients with lung cancer, who also often have advanced cancer, controlling cough and providing cough-free periods is highly important for patients from a quality-of-life perspective. In these cases, other experimental approaches may be used and trialed. We have examples in the literature of case studies in which physicians have used gamma aminobutyric acid agonists (such as baclofen), 21 diazepam, 19 paroxetine (in concomitant pruritus and cough), 49 amitriptyline, 50 gabapentin, 50, 51 carbamazepine, 50 and thalidomide, 52 although many of these refer to chronic cough or cough in respiratory diseases other than cancer and could be tried in the lung cancer setting in an N-of-1 trial.
On occasion, complications of coughing 53 may be debilitating and not responsive to any medications. In such circumstances, physicians may consider trying other medications even when treatment decisions cannot be based on existing evidence. In such cases, single case experiments, also referred to as "N-of-1 randomized controlled trials (RCTs)," 54 should be considered because N-of-1 RCTs are the most rigorous design for establishing efficacy of treatment in individual patients. 54 The key elements in performing such trials are (1) obtaining informed consent, (2) randomizing two treatments (eg, active therapy or placebo or alternative therapy) determined by random allocation preferably with crossover, (3) double blinding, and (4) measuring a cough outcome important to the patient. 54 Because ethical issues of N-of-1 RCTs are different than those of standard RCTs involving other patients, institutional review board approval and informed written consent may not be necessary. However, consultation with the institutional review board and reading more about how to set up an N-of-1 RCT program are advised prior to starting such a program. 54 Also, the costs of preparing the placebo should be considered because it may be a barrier to developing the program. N-of-1 RCTs with placebo control groups may not be practical in a private or clinical setting, in which case an unblended N-of-1 trial, although less scientifically rigorous and robust, may be an alternative approach.
Areas of Future Research
In the field of cough management for patients with lung cancer, in which the evidence base is minimal and highly at risk of bias because of serious methodologic problems, there is an urgent need to invest more on research and In 2015, a single-arm double-blind crossover trial using a neurokinin-1 receptor antagonist (aprepitant) showed significant reductions in cough counts and reported cough severity in a small sample of patients with lung cancer, 55 and this is a pathway that may be a key component of cough mechanisms in lung cancer that should be further evaluated. The latter trial was reported only as a meeting abstract at this time, so it is not used in the main evidence base for our recommendations.
The range of cough syrups sold over the counter should be a focus in future research in patients with lung cancer, as they contain substances such as dextromethorphan, glycerol, antihistamines, and guaifenesin that, if found effective, would be cost-effective approaches with minimal side effect burdens. Future research should benefit from using validated patient reported outcomes or cough counting (subjective and objective measures) in a relevant lung cancer population. At this time, there is only one cough-related quality-of-life scale specifically developed for patients with lung cancer, 56 and its use should be considered in future trials, alongside simple visual analog scales and more objective measures of cough counts. Symptom burden may be another appropriate outcome measure in trials of managing cough alongside other symptoms in patients with lung cancer.
As a significant percentage of patients with lung cancer have (diagnosed or undiagnosed) COPD, a focus of future research should also be to assess the role of bronchodilator therapy (and/or inhaled corticosteroids) for patients with lung cancer and COPD. At present, it is currently unclear whether these therapies are effective for cough among patients with COPD without lung cancer. In the same mode, other patient comorbidities (eg, gastroesophageal reflux disease) can be considered as the focus of treatment.
An area that we should explore more concretely is the role of smoking cessation in the symptomatic relief of cough. A large trial of smoking cessation peridiagnosis with lung cancer has shown that patients who quit smoking had a survival advantage (28 vs 18 mo) over those who did not. 57 There may well be a role for this approach in reducing respiratory symptoms in lung cancer, and this needs to be explored.
There is also no information in the literature about cough and hemoptysis, an area that warrants more research, and the role of local treatments such as brachytherapy or tranexamic acid, and so on.
Conclusions
Compared with the 2006 CHEST Cough Guidelines, the current recommendations and suggestions are based on a Cochrane systematic review, 15 are more specific, and follow a step-up approach to the management of cough among patients with lung cancer, acknowledging the low quality evidence in the field and the urgent need for developing a more concrete evidence base through highquality research. The strength of recommendations and suggestions made in this guideline clearly show that research in this symptom management field is lagging behind research in other symptoms in oncology. This article has also identified gaps in our knowledge and areas for future research.
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